AMY2B

Across TCGA pan-cancer cohorts, AMY2B RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of AMY2B’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where AMY2B RNA is repressed in tumor relative to normal tissue. In most cancer types AMY2B is over-expressed in tumor, although a few such as LUSC and BLCA show the opposite, repressed pattern.

LUSC, BLCA, and UCEC are the cancer types where AMY2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AMY2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	Male	II,III,IV	−0.923	<.001	7	view →
BLCA	Male	All	−0.913	.001	7	view →
UCEC	All	All	−1.206	<.001	6	view →
BRCA	All	III,IV	−1.198	<.001	6	view →
LIHC	All	All	+0.439	.001	5	view →
LUAD	Male	III,IV	−0.565	.007	4	view →
HNSC	All	All	−0.413	.010	4	view →
KIRC	All	All	+0.316	<.001	4	view →
CHOL	All	All	+1.211	.002	2	view →
KICH	All	All	−0.352	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

AMY2B–LUSC

Open the LUSC breakdown →